On November 6th, Nuo He Nord (Shanghai) Medical Trade Co., Ltd. (hereinafter referred to as “Nuo He Nord Shanghai”) and Shangye Holdings Co., Ltd. (hereinafter referred to as “Pharmaceutical Holdings”) were at the 5th China International Import Expo A strategic cooperation signing was held on the spot.
Wei Mingke, the Consul General of the Kingdom of Denmark in Shanghai, Zhang Qing, deputy director of the Shanghai Pharmaceutical Supervision Bureau, Shi Lan, director of the Drug Administration of the Shanghai Pharmaceutical Supervision Bureau, Tang Peng, Nuo He, deputy director of the Comprehensive Insurance Office of the Shanghai Lingang New Section District Management Committee Zhou Xiaping, senior vice president and president of the Greater China, the vice president of Nuo and Noord Business Department, Vice President of Nordr’s Compliance and Law Department, Mana, Executive Director of Shanghai Medical Pharmaceutical Li Yongzhong, Ren Gang, deputy general manager of Shangyao Holdings, chairman of the Shanghai Medicine and Relief Center, Ren Gang, chairman of Shang Drug Medical Devices, Song Yan, deputy general manager of Shangyao Holdings, General Manager of the International Supply Chain of Shangyao, and General Manager of the National Procurement Center attended the signing ceremony. Essence
Novo and Norders signed a contract with the Pharmaceutical Holdings at the Fifth Expo
Based on this contract, the drug holding will provide Nuo and Nond Shanghai to provide intelligent modern logistics warehouses through the innovative pharmaceutical third -party logistics service method, and To further meet the future business development needs of Nuo and Nord, help Nuo and Nord better serve Chinese patients.
Zhang Qing, deputy director of the Shanghai Drug Administration, said that the Municipal Drug Administration supports and affirmed the cooperation between the drug holding and Noord and Nord. This cooperation has sufficient innovation, forward -looking, and demonstration. It is the useful exploration of the partnership of the drug holding cooperative industry to participate in the global medical industry and integrate into the international and domestic dual -cycle. Important measures to innovate the biomedical industry with international influence. It is hoped that the Pharmaceutical Holdings and Novo and Noord will work hard in the future cooperation, and make this cooperation project a bright business card in the new area of the Lingang Hong Kong, and contribute to the new round of high -quality development in Shanghai’s biomedical industry in Shanghai. Essence
Zhou Xiaping, a senior vice president and president of Greater China, said: “During the Expo last year, Nuo and Nord reached a cooperation with the medicine to benefit patients. Logistics Warehouse Center. This investment construction is an important step in Nuo and Nord’s implementation of the newly layout of the three engines’ entire industrial chain. Better serve Chinese patients. “
Li Yongzhong, the executive director, deputy president and general manager of Shanghai Medicine Holdings, said that this year is the 70th anniversary of the establishment of the medicine holding. Since its establishment in 1952, Shangyao Holdings has always adhered to the business philosophy of “service as the pride”. Efforts have been developed into China’s second largest pharmaceutical distribution enterprise. The sources of cooperation with Nuo and Noord in the medicine holding have a long history. Since 1994, the medicine has maintained in -depth and friendly cooperation with Novo and Nord. In the past 20 years, the drug holding has participated in Nuo and Nord’s heavy products. Listing and cooperation, all these efforts have made the cooperation between the two parties grow steadily. The signing of the strategic cooperation will be the innovation breakthrough of the two parties in the logistics of the medicine. This will not only meet the needs of the international business development of the drug holding, but also meet the development plan of the “Fourteenth Five -Year Plan” development plan. Holdings responded to the Shanghai Municipal Government to build a world -class biopharmaceutical industry cluster and promote the call of high -quality development of the biomedical industry.
During the five years of the Expo, Novo has invested in China five times. In this Expo, Nuo and Noord announced the investment of 400 million yuan to set up Novo Nordon (Shanghai) Investment Co., Ltd. in Shanghai Lingang area. All business engines such as R & D realize control, upgrade to achieve the strategic layout of “dual centers, three engines”, combined with the advantages of economic development in different regional economic development in Shanghai, Tianjin, and Beijing to promote mutual promotion and promote China’s business into a new stage of development. At the same time, Nuo and Nord focused on showing 14 innovative medicines in the field of diabetes, hemophilia, and growth disorders at the Expo. Ambition.